Skip to content

Home
IOncology
Infectious Desease Frontier
IHepatology
Hematology Frontier
Conference topics
Experts Interviews
Informations
Live Broadcasting
Logout

Connecting Medical Expertise through Media

Search for:

Home
IOncology
Infectious Disease Frontier
International Hepatology
Hematology Frontier
Conference topics
Experts’ Interviews
Informations

Home
IOncology
Infectious Disease Frontier
International Hepatology
Hematology Frontier
Conference topics
Experts’ Interviews
Informations

Search for:

Posted inIOncology

ASCO 2026 | Prof. Li Mao: Ensartinib’s Global Strategy in the Intensifying ALK+ NSCLC Landscape

Posted by

By Mourabit Halima 2026.07.01Posted inIOncology0 Shares

Home » ASCO 2026 | Prof. Li Mao: Ensartinib’s Global Strategy in the Intensifying ALK+ NSCLC Landscape

YouTube player

Post Views: 1,513

Share via:

Facebook
X (Twitter)
LinkedIn
More

Last updated on 2026.07.01

Mourabit Halima

Post navigation

Previous Post

ASCO 2026 | Prof. Kohei Shitara: T-DXd Establishes the New Standard for Second-Line HER2-Positive Advanced Gastric Cancer, with China’s Contributions Driving Global Progress

ASCO 2026 | Prof. Kohei Shitara: T-DXd Establishes the New Standard for Second-Line HER2-Positive Advanced Gastric Cancer, with China’s Contributions Driving Global Progress

Next Post

APPLE 2026 | Academician Jia Fan Invites You to APPLE 2026 in Shanghai: Witness China’s Growing Global Leadership in Liver Cancer and Explore AI-Driven Innovation

APPLE 2026 | Academician Jia Fan Invites You to APPLE 2026 in Shanghai: Witness China’s Growing Global Leadership in Liver Cancer and Explore AI-Driven Innovation

LinkedIn
Twitter
Mail

Related Media:

Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
Paris, France

Facebook
X (Twitter)
LinkedIn
More Networks

Share via

Copy link

CopyCopied